{
    "clinical_study": {
        "@rank": "109265", 
        "arm_group": [
            {
                "arm_group_label": "AL-60371/Posology 1", 
                "arm_group_type": "Experimental", 
                "description": "AL-60371 otic suspension, single dose of 200 \u00b5L following surgical insertion of tympanostomy tubes"
            }, 
            {
                "arm_group_label": "AL-60371/Posology 2", 
                "arm_group_type": "Experimental", 
                "description": "AL-60371 otic suspension, single dose of 4 drops following surgical insertion of tympanostomy tubes"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to describe the pharmacokinetics of AL-60371 otic suspension\n      following two posologies of bilateral ototopical doses in pediatric subjects immediately\n      after bilateral tympanostomy tube surgery."
        }, 
        "brief_title": "Pharmacokinetic Study of AL-60371 Otic Suspension in Pediatric Subjects Following Tympanostomy Tube Surgery", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Otitis Media", 
        "condition_browse": {
            "mesh_term": [
                "Otitis", 
                "Otitis Media"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Requires bilateral myringotomy and tympanostomy tube insertion;\n\n          -  Provides informed consent (parent/legal guardian);\n\n          -  Signs assent form where applicable (subject);\n\n          -  Accompanied by parent/legal guardian at each visit;\n\n          -  Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Menarcheal females;\n\n          -  Current or recent history of any disease which, in the opinion of the Principal\n             Investigator, may place the subject at risk or interfere with study;\n\n          -  Use of excluded medications within one week prior to surgery and for the duration of\n             the study;\n\n          -  Requires another surgical procedure in addition to the myringotomy;\n\n          -  Clinically relevant otic condition which, in the opinion of the Principal\n             Investigator, would preclude the safe administration of the study medication;\n\n          -  Participation in any other investigational study within 30 days before entry into\n             this study or along with this study;\n\n          -  Known or suspected allergy or hypersensitivity to any active or inactive ingredient\n             in the test article;\n\n          -  Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Years", 
            "minimum_age": "6 Months"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908764", 
            "org_study_id": "C-13-023"
        }, 
        "intervention": {
            "arm_group_label": [
                "AL-60371/Posology 1", 
                "AL-60371/Posology 2"
            ], 
            "intervention_name": "AL-60371 otic suspension", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "ear tubes", 
            "tympanostomy tubes", 
            "Otitis Media at the time of Tympanostomy Tube surgery", 
            "OMTT"
        ], 
        "lastchanged_date": "April 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fort Worth", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "76134"
                }, 
                "name": "Contact Alcon Call Center for Trial Locations"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Single Dose, Pharmacokinetic Study of AL-60371 Otic Suspension, 0.3% in Pediatric Subjects Following Tympanostomy Tube Surgery", 
        "overall_contact": {
            "email": "alcon.medinfo@alcon.com", 
            "last_name": "Alcon Call Center", 
            "phone": "1-888-451-3937"
        }, 
        "overall_official": {
            "affiliation": "Alcon Research", 
            "last_name": "Celeste McClean, BS, MT (ASCP)", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).", 
                "measure": "Maximum observed analyte plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose"
            }, 
            {
                "description": "The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).", 
                "measure": "Time to reach Cmax (Tmax)", 
                "safety_issue": "No", 
                "time_frame": "Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose"
            }, 
            {
                "description": "The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).", 
                "measure": "Area under the analyte plasma concentration-time curve to the last quantifiable sampling time point (AUC0-last)", 
                "safety_issue": "No", 
                "time_frame": "Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose"
            }, 
            {
                "description": "The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).", 
                "measure": "Area under the concentration-time curve from 0 to infinity (AUC0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose"
            }, 
            {
                "description": "The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).", 
                "measure": "Time to last measurable concentration (Tlast)", 
                "safety_issue": "No", 
                "time_frame": "Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose"
            }, 
            {
                "description": "The analyte plasma concentrations at each collection time point will be quantitated using a high performance liquid chromatography/tandem mass spectrometry method (HPLC/MS/MS).", 
                "measure": "The terminal elimination half (T\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "Day 1/Surgery Pre-dose, 15 minutes, 30 minutes, 1, 2, 4, 6 hours post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Alcon Research", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alcon Research", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}